Form 4: Recursion Pharmaceuticals Director Sun Elaine D Reports Acquisition of Restricted Stock Units and Stock Options

Director Sun Elaine D reports acquisition of restricted stock units and stock options in Recursion Pharmaceuticals, granted under the company's Outside Director Compensation Policy.

Summary

• On March 17, 2025, Sun Elaine D, a director of Recursion Pharmaceuticals, acquired 36,549 shares of Class A Common Stock.
• These shares were granted as restricted stock units under Recursion's Outside Director Compensation Policy.
• The restricted stock units will vest in three equal installments on the anniversaries of March 17, 2025, contingent upon continued service.
• Additionally, Sun Elaine D acquired options to purchase 73,099 shares of Class A Common Stock at an exercise price of $6.84.
• These options were also granted under the Outside Director Compensation Policy and vest in three equal installments on the anniversaries of March 17, 2025, contingent upon continued service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The filing indicates standard director compensation practices, aligning director interests with shareholders through equity grants.

Positives

• The grant of restricted stock units and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The director's holdings will increase over time as the restricted stock units and stock options vest, assuming continued service.

Industry Context

Director compensation packages often include stock options and restricted stock units to incentivize performance and align interests with shareholders. This filing reflects a standard practice in publicly traded companies.

Comparison to Industry Standards

• Director compensation packages vary across the pharmaceutical industry, but typically include a mix of cash, equity, and benefits.
• Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also utilize stock options and restricted stock units as part of their director compensation plans.
• The vesting schedules and exercise prices are generally designed to incentivize long-term value creation.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align the director's interests with the company's long-term success.
• Employees may see the grants as a sign of confidence in the company's future.

Next Steps

• The director will continue to vest in the restricted stock units and stock options over the next three years, contingent upon continued service.
• The director may exercise the stock options at her discretion after they vest.

Key Dates

Keywords

Recursion Pharmaceuticals, Director Compensation, Stock Options, Restricted Stock Units, Beneficial Ownership, Form 4, RXRX